**Author details**

Ján Varga Department of Gynaecology and Obstetrics, Faculty of Medicine, P.J. Šafárik University, L. Pasteur University Hospital, Košice, Slovakia

\*Address all correspondence to: janko.varga@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**49**

*Ovarian Cancer Tumour Biology: Genesis DOI: http://dx.doi.org/10.5772/intechopen.98289*

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;**68**:394-424. DOI:

[8] Bowen NJ, LDe W, Matyunina LV, et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Medical Genomics. 2009;**2**:71. DOI: 10.1186/1755-8794-2-71

[9] Barker N, Ridgway RA, Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;**457**:608-

[10] Kuhn E, Kurman RJ, IeM S. Ovarian cancer is an imported disease: Fact or fiction? Current Obstetrics and Gynecology Reports. 2012;**1**:1-9. DOI:

611. DOI: 10.1038/nature07602

10.1007/s13669-011-0004-1

the emperor have no clothes? Gynecologic Oncology. 1999;**72**:437- 442. DOI: 10.1006/gyno.1998.5275

journal.pone.0232487

10.1016/j.canep.2020.101700

features of paired cases of

tumor and subsequent serous carcinoma. The American Journal of Surgical Pathology. 2019;**43**:1462-1472. DOI: 10.1097/PAS.0000000000001325

et al. Dysplastic changes in

[11] Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does

[12] Sunde J, Wasickanin M, Katz TA, et al. Prevalence of endosalpingiosis and other benign gynecologic lesions. PLoS One. 2020;**15**:e0232487. DOI: 10.1371/

[13] Hermens M, Altena AM, Bulten J, et al. Increased association of ovarian cancer in women with histological proven endosalpingiosis. Cancer Epidemiology. 2020;**65**:101700. DOI:

[14] Chui MH, Xing D, Zeppernick F, et al. Clinicopathologic and molecular

metachronous ovarian serous borderline

[15] Piek JM, van Diest PJ, Zweemer RP,

prophylactically removed fallopian

Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. Current Treatment Options in Oncology. 2015;**16**:318. DOI: 10.1007/

[3] Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. Journal of Clinical Oncology. 2019;**37**: 2317-2328. DOI: 10.1200/JCO.19.

[4] Shih LEM, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. The American Journal of Pathology. 2004;**164**:1511-1518. DOI: 10.1016/s0002-9440(10)63708-x

[5] Kurman RJ, IeM S. The dualistic model of ovarian carcinogenesis: Revisited, revised and expanded. The American Journal of Pathology. 2016;**186**:733-747. DOI: 10.1016/j.

[6] Peres LC, Cushing-Haugen KL, Anglesio M, et al. Histotype

classification of ovarian carcinoma: A comparison of aproaches. Gynecologic Oncology. 2018;**151**:53-60. DOI: 10.1016/j.ygyno.2018.08.016

[7] Klotz DM, Wimberger P. Cells of origin of ovarian cancer: Ovarian surface epithelium or fallopian tube? Archives of Gynecology and Obstetrics. 2017;**296**:1055-1062. DOI: 10.1007/

ajpath.2015.11.011

s00404-017-4529-z

**References**

10.3322/caac.21492

s11864-014-0318-0

01009

[2] Schmid BC, Oehler MK.

*Ovarian Cancer Tumour Biology: Genesis DOI: http://dx.doi.org/10.5772/intechopen.98289*
